Biological Chemistry II Unit 4 ReviewAmino Acid and Protein Metabolism

Amino Acid Structure and Properties

• Amino acids are organic compounds containing an amino group (-NH2), a carboxyl group (-COOH), and a side chain (R group) attached to a central α-carbon
• The 20 standard amino acids are classified based on the properties of their side chains (nonpolar, polar, acidic, or basic)
  • Nonpolar amino acids (alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine) have hydrophobic side chains
  • Polar amino acids (serine, threonine, cysteine, asparagine, glutamine) have hydrophilic side chains that can form hydrogen bonds
• Amino acids are zwitterions at physiological pH, meaning they have both positive (protonated amino group) and negative (deprotonated carboxyl group) charges
• The isoelectric point (pI) is the pH at which an amino acid has a net charge of zero
• Amino acids can undergo condensation reactions to form peptide bonds, linking them together to create polypeptides and proteins
• The sequence of amino acids in a protein, known as its primary structure, determines its unique three-dimensional structure and function
• Amino acids can also serve as precursors for the synthesis of other important biomolecules (neurotransmitters, hormones, and nucleotides)

Protein Structure and Folding

• Proteins have four levels of structure: primary, secondary, tertiary, and quaternary
• Primary structure refers to the linear sequence of amino acids in a polypeptide chain
• Secondary structure involves local folding of the polypeptide chain into regular patterns (α-helices and β-sheets) stabilized by hydrogen bonds
  • α-helices are right-handed spiral conformations with 3.6 amino acids per turn
  • β-sheets are formed by extended polypeptide chains that are held together by hydrogen bonds between the backbone atoms of adjacent strands
• Tertiary structure is the three-dimensional arrangement of a single polypeptide chain, resulting from interactions between side chains (hydrophobic interactions, hydrogen bonds, ionic bonds, and disulfide bridges)
• Quaternary structure refers to the assembly of multiple polypeptide subunits into a functional protein complex
• Protein folding is driven by the thermodynamic tendency to minimize the exposure of hydrophobic residues to the aqueous environment while maximizing entropy
• Chaperones are proteins that assist in the proper folding of other proteins by preventing aggregation and misfolding
• Misfolded proteins can lead to cellular dysfunction and are associated with various diseases (Alzheimer's, Parkinson's, and Huntington's)

Amino Acid Biosynthesis

• Amino acids can be classified as essential (must be obtained from the diet) or nonessential (can be synthesized by the body)
• The biosynthesis of nonessential amino acids occurs through various metabolic pathways, often using intermediates from glycolysis, the citric acid cycle, or the pentose phosphate pathway
• Transamination is a key process in amino acid biosynthesis, involving the transfer of an amino group from an amino acid to an α-ketoacid, catalyzed by transaminases
• Glutamate is a central molecule in amino acid metabolism, serving as a major amino group donor in transamination reactions
• The biosynthesis of aromatic amino acids (phenylalanine, tyrosine, and tryptophan) occurs through the shikimate pathway in plants and microorganisms
• Asparagine is synthesized from aspartate and glutamine by asparagine synthetase, while glutamine is produced from glutamate and ammonia by glutamine synthetase
• Serine biosynthesis involves a three-step pathway starting from 3-phosphoglycerate, an intermediate of glycolysis
• Cysteine is synthesized from serine and homocysteine through the transsulfuration pathway, which also involves the formation of cystathionine

Protein Synthesis and Translation

• Protein synthesis is the process by which cells produce proteins based on the genetic information encoded in mRNA
• Translation is the stage of protein synthesis where the genetic code is decoded to produce a specific sequence of amino acids
• The genetic code is a set of three-nucleotide codons that specify which amino acid will be added to the growing polypeptide chain during translation
  • The genetic code is degenerate, meaning that multiple codons can code for the same amino acid
  • Start codons (AUG) initiate translation, while stop codons (UAA, UAG, UGA) terminate the process
• Ribosomes are the molecular machines responsible for catalyzing the formation of peptide bonds during translation
  • Ribosomes consist of two subunits (large and small) composed of ribosomal RNA (rRNA) and proteins
• Transfer RNAs (tRNAs) are adapter molecules that link the genetic code to the amino acids being incorporated into the growing polypeptide chain
  • Each tRNA has an anticodon that base-pairs with the corresponding codon on the mRNA
• Translation occurs in three stages: initiation, elongation, and termination
  • Initiation involves the assembly of the ribosomal subunits, mRNA, and initiator tRNA at the start codon
  • Elongation is the cyclic process of adding amino acids to the growing polypeptide chain based on the sequence of codons in the mRNA
  • Termination occurs when a stop codon is encountered, leading to the release of the completed polypeptide and the dissociation of the ribosomal subunits
• Post-translational modifications (phosphorylation, glycosylation, and proteolytic cleavage) can further modify proteins after translation, influencing their structure, function, and localization

Protein Degradation and Turnover

• Protein degradation is the process by which cells break down proteins into their constituent amino acids for recycling or energy production
• The two major pathways for protein degradation are the ubiquitin-proteasome system (UPS) and autophagy
• The UPS targets specific proteins for degradation by tagging them with ubiquitin, a small regulatory protein
  • Ubiquitination involves the sequential action of three enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase)
  • Polyubiquitinated proteins are recognized and degraded by the 26S proteasome, a large multisubunit protein complex
• Autophagy is a cellular process that targets cytoplasmic components, including organelles and protein aggregates, for degradation in lysosomes
  • Macroautophagy involves the formation of a double-membrane vesicle (autophagosome) that engulfs cytoplasmic material and fuses with lysosomes for degradation
  • Chaperone-mediated autophagy (CMA) targets specific proteins with a KFERQ motif for translocation into lysosomes via the LAMP2A receptor
• Protein turnover refers to the balance between protein synthesis and degradation, which is essential for maintaining cellular homeostasis and responding to changing environmental conditions
• The half-life of a protein is the time it takes for half of the protein to be degraded, which can range from minutes to days depending on the protein's function and regulation
• Abnormalities in protein degradation pathways are associated with various diseases (neurodegenerative disorders, cancer, and metabolic syndromes)

Amino Acid Catabolism

• Amino acid catabolism is the process by which amino acids are broken down to generate energy or to serve as precursors for the synthesis of other biomolecules
• The first step in amino acid catabolism is the removal of the amino group, typically through transamination or deamination reactions
  • Transamination transfers the amino group to an α-ketoacid, forming a new amino acid and α-ketoacid
  • Deamination removes the amino group as ammonia, which is then converted to urea for excretion
• The carbon skeletons of amino acids can be converted into various metabolic intermediates (pyruvate, acetyl-CoA, or intermediates of the citric acid cycle) for energy production or biosynthesis
• Glucogenic amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, histidine, methionine, proline, serine, threonine, and valine) can be converted into glucose through gluconeogenesis
• Ketogenic amino acids (leucine and lysine) can be converted into ketone bodies, which serve as an alternative energy source for the brain during prolonged fasting or starvation
• Some amino acids have unique catabolic pathways:
  • Phenylalanine and tyrosine are catabolized through the formation of fumarate and acetoacetate
  • Tryptophan is catabolized through the kynurenine pathway, generating NAD+ and other neuroactive compounds
  • Branched-chain amino acids (leucine, isoleucine, and valine) are catabolized through a shared pathway involving branched-chain aminotransferases and dehydrogenases
• Disorders of amino acid catabolism can lead to the accumulation of toxic intermediates and cause various metabolic diseases (phenylketonuria, maple syrup urine disease, and homocystinuria)

Metabolic Disorders of Amino Acids

• Metabolic disorders of amino acids are genetic conditions caused by defects in enzymes involved in amino acid metabolism, leading to the accumulation of toxic intermediates or the deficiency of essential products
• Phenylketonuria (PKU) is caused by a deficiency in phenylalanine hydroxylase, leading to the accumulation of phenylalanine and its toxic derivatives in the blood and brain
  • Untreated PKU can cause intellectual disability, seizures, and other neurological symptoms
  • Management of PKU involves a strict low-phenylalanine diet and regular monitoring of blood phenylalanine levels
• Maple syrup urine disease (MSUD) is caused by a defect in the branched-chain α-ketoacid dehydrogenase complex, leading to the accumulation of branched-chain amino acids and their corresponding α-ketoacids
  • MSUD is characterized by a distinct maple syrup odor in the urine, as well as neurological symptoms, feeding difficulties, and metabolic decompensation
  • Treatment of MSUD involves a diet low in branched-chain amino acids and prompt management of metabolic crises
• Homocystinuria is caused by defects in the enzymes involved in the metabolism of homocysteine, leading to its accumulation in the blood and urine
  • Elevated homocysteine levels are associated with an increased risk of thromboembolism, lens dislocation, and skeletal abnormalities
  • Treatment of homocystinuria typically involves a methionine-restricted diet, betaine supplementation, and vitamin B6, B12, and folate supplementation
• Urea cycle disorders are a group of metabolic disorders caused by defects in the enzymes of the urea cycle, leading to the accumulation of ammonia and other toxic intermediates
  • Symptoms of urea cycle disorders include vomiting, lethargy, seizures, and coma due to hyperammonemia
  • Management of urea cycle disorders involves a low-protein diet, amino acid supplementation, and medications to remove excess ammonia (sodium benzoate and sodium phenylbutyrate)
• Newborn screening programs have been established in many countries to identify infants with metabolic disorders early and initiate prompt treatment to prevent long-term complications

Applications in Biochemistry and Medicine

• Understanding amino acid and protein metabolism has numerous applications in biochemistry and medicine, enabling the development of new diagnostic tools, therapies, and biotechnological innovations
• Recombinant protein production involves the use of genetically engineered cells (bacteria, yeast, or mammalian cells) to produce large quantities of specific proteins for research, therapeutic, or industrial purposes
  • Examples of recombinant proteins include insulin, growth hormones, and monoclonal antibodies
• Protein engineering techniques (site-directed mutagenesis and directed evolution) allow researchers to modify the structure and function of proteins to enhance their stability, specificity, or catalytic activity
  • Engineered proteins have applications in biocatalysis, biosensors, and drug design
• Amino acid supplementation is used in various clinical settings to support growth, wound healing, and recovery from illness or surgery
  • Enteral and parenteral nutrition formulas contain balanced mixtures of essential and nonessential amino acids to meet the nutritional needs of patients unable to consume adequate protein through diet
• Dietary management of metabolic disorders (PKU, MSUD, and homocystinuria) involves the restriction of specific amino acids and the supplementation of essential nutrients to prevent the accumulation of toxic intermediates
• Amino acid analogs and inhibitors of amino acid metabolism are used as therapeutic agents for various diseases
  • L-DOPA, a precursor of dopamine, is used in the treatment of Parkinson's disease to replenish dopamine levels in the brain
  • Methotrexate, an inhibitor of folate metabolism, is used as a chemotherapeutic agent and immunosuppressant
• Biomarkers of amino acid and protein metabolism (plasma amino acid profiles, urine organic acids, and enzyme activity assays) are used in the diagnosis and monitoring of metabolic disorders
• Research on the role of amino acid metabolism in cancer has led to the development of targeted therapies that exploit the altered metabolic requirements of cancer cells
  • Asparaginase, an enzyme that depletes asparagine, is used in the treatment of acute lymphoblastic leukemia (ALL) due to the dependence of ALL cells on exogenous asparagine
• Personalized nutrition and precision medicine approaches aim to tailor dietary recommendations and therapeutic interventions based on an individual's genetic background, metabolic profile, and environmental factors, taking into account variations in amino acid requirements and metabolism